C. Slapak

发表

Failure Modes in Anticancer Drug Discovery and Development

R. Walgren, C. Slapak, 2014 .

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

C. Slapak, D. Spriggs, E. Haura, 2011, Cancer Chemotherapy and Pharmacology.

PNEUMOCYSTIS CARINII PNEUMONIA AS A COMPLICATION OF DESFERRIOXAMINE THERAPY

C. Slapak, P. Kouides, L. Rosenwasser, 1988, British journal of haematology.

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

C. Slapak, E. Roeland, R. Ilaria, 2017, Journal of Hematology & Oncology.

A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.

J. Aster, R. Soiffer, R. Stone, 1995, Blood.

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

J. Schellens, H. Rosing, J. Beijnen, 2008, Clinical Cancer Research.

Reversal of Multidrug Resistance with LY335979: Functional Analysis of P‐glycoprotein‐Mediated Transport Activity and Its Modulation In Vivo

D. Piwnica-Worms, C. Slapak, J. Dahlheimer, 2001 .

Reversal of Multidrug Resistance with LY335979: Functional Analysis of P‐glycoprotein‐Mediated Transport Activity and Its Modulation In Vivo

D. Piwnica-Worms, C. Slapak, J. Dahlheimer, 2001, Journal of clinical pharmacology.

Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation.

R. Weichselbaum, C. Thompson, D. Kufe, 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Identification and characterization of the canine multidrug resistance-associated protein.

C. Slapak, A. Dantzig, Liandong Ma, 2002, Molecular cancer therapeutics.

Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.

J. Lecerf, P. Fracasso, D. Toppmeyer, 1994, Cancer research.

P-Glycoprotein Expression Decreased Anthracycline Uptake Precedes Increased Murine Erythroleukemia Cells under Adriamycin Selection : Sequential Emergence of Distinct Resistance Phenotypes in Updated

C. Slapak, S. Levy, J. Daniel, 2006 .

Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.

C. Slapak, S. Levy, J. Daniel, 1990, Cancer research.

Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters.

C. Slapak, Sheng-Bin Peng, D. Paul, 2004, Biochemical pharmacology.

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies

D. Toppmeyer, C. Slapak, L. Green, 2002 .

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

A. Oza, L. Seymour, M. Moore, 2005, Cancer Chemotherapy and Pharmacology.

Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

J. Rader, J. Schellens, P. Fracasso, 2004, Clinical Cancer Research.

Differential protection of normal and malignant human myeloid progenitors (CFU-GM) from Ara-C toxicity using cycloheximide

R. Fine, C. Slapak, C. Richman, 1985 .

Differential protection of normal and malignant human myeloid progenitors (CFU-GM) from Ara-C toxicity using cycloheximide.

R. Fine, C. Slapak, C. Richman, 1985, Blood.

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

I. Flinn, S. de Vos, K. Foon, 2015, Leukemia & lymphoma.

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

S. de Vos, K. Ganjoo, C. Slapak, 2012, Clinical Cancer Research.

Advances in Brief An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines

L. Gelbert, C. Slapak, J. Davidson, 2004 .

A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.

C. Slapak, L. Green, C. Sweeney, 2004, Clinical Cancer Research.

Role of P-glycoprotein in dolastatin 10 resistance.

D. Kufe, D. Toppmeyer, C. Slapak, 1994, Biochemical pharmacology.

Defective translocation of protein kinase C in multidrug-resistant HL-60 cells confers a reversible loss of phorbol ester-induced monocytic differentiation.

D. Kufe, S. Kharbanda, C. Slapak, 1993, The Journal of biological chemistry.

Reversal of Multidrug Resistance with LY335979: Functional Analysis of P‐glycoprotein‐Mediated Transport Activity and Its Modulation In Vivo

D. Piwnica-Worms, C. Slapak, J. Dahlheimer, 2001, Journal of clinical pharmacology.

A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

J. Vose, K. Savage, D. Neuberg, 2005 .

Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells.

C. Slapak, L. Green, P. Marder, 2001, Biochemical pharmacology.

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

S. Estrem, C. Slapak, A. Cleverly, 2015, Drug design, development and therapy.

Synthesis and chemistry of 2-trimethylsilylbenzocyclobutenones

C. Slapak, B. Chenard, D. K. Anderson, 1981 .

An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines

L. Gelbert, C. Slapak, J. Davidson, 2004, Cancer Research.

Treatment of acute myeloid leukemia in the elderly with low‐dose cytarabine, hydroxyurea, and calcitriol

C. Slapak, K. Miller, J. Desforges, 1992, American journal of hematology.

Expression of c-fos precedes MDR3 in vincristine and adriamycin selected multidrug resistant murine erythroleukemia cells.

C. Slapak, A. Bhushan, S. Levy, 1996, Biochemical and Biophysical Research Communications - BBRC.

Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.

C. Slapak, S. Hurwitz, M. Terashima, 1997, Blood.

CHAPTER 18 – Failure modes in anticancer drug discovery and development

C. Slapak, K. Blanchard, H. Pearce, 2008 .

Abrogation of Mitochondrial Cytochrome c Release and Caspase-3 Activation in Acquired Multidrug Resistance*

E. Alnemri, B. Teicher, D. Kufe, 1998, The Journal of Biological Chemistry.

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

J. Vose, A. LaCasce, S. de Vos, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

M. Ranson, P. Price, J. Matthews, 2010, Clinical Cancer Research.

Clinical development of galunisertib ( LY 2157299 monohydrate ) , a small molecule inhibitor of transforming growth factorbeta factorbeta factorbeta signaling pathway

S. Estrem, C. Slapak, A. Cleverly, 2015 .

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

J. Schellens, J. Beijnen, E. Voest, 2011, Clinical Cancer Research.

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

C. Slapak, L. Green, C. Sweeney, 2004, Clinical Cancer Research.

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors

C. Slapak, T. Tamura, N. Yamamoto, 2013, Cancer Chemotherapy and Pharmacology.

Effect of glucose transport inhibitors on vincristine efflux in multidrug-resistant murine erythroleukaemia cells overexpressing the multidrug resistance-associated protein (MRP) and two glucose transport proteins, GLUT1 and GLUT3.

C. Slapak, S. Levy, R. Martell, 1997, British Journal of Cancer.

Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells.

D. Kufe, C. Slapak, N. Mizunuma, 1994, Blood.

Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity.

C. Slapak, C. Richman, B. Toh, 1990, Journal of biological response modifiers.

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

C. Slapak, E. Roeland, J. Goldman, 2015 .

Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).

C. Slapak, S. Levy, M. Terashima, 1996, Biochemical pharmacology.

A very early induction of major vault protein accompanied by increased drug resistance in U‐937 cells

L. Rome, V. Devanarayan, A. Stephen, 2002, International journal of cancer.